18F fluciclovine not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus”In the company’s words, NCT04410133 on ClinicalTrials.gov
- Tested for
- Brain Metastases (2 trials)
- Main trialPhase 3
- “An open-label, single dose, single arm, prospective, multicenter Phase 3 study to establish the diagnostic performance of 18F fluciclovine positron emission tomography (PET) in detecting recurrent brain metastases after radiation therapy”In the company’s words, NCT04410133 on ClinicalTrials.gov
- Other names
- Axumin
Other drugs for Brain Metastases
- Floretyrosine FTelix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- 131I-IPATelix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- HBI-8000HUYABIO International, LLC. · Phase 3
- Trastuzumab deruxtecanDaiichi Sankyo · AstraZeneca · Phase 3
- Allogeneic genetically modified gamma-delta T cellsIn8bio Inc. · Phase 1/2
- Autologous genetically modified gamma-delta T cellsIn8bio Inc. · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 5 Jun 2023 | Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases | |
| Phase 2Completed | 31 Dec 2021 | Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026